TET proteins: On the frenetic hunt for new cytosine modifications

Briefings in Functional Genomics

Volumn 12, Issue 3, 2013, Pages 191-204

  Delatte, Benjamin ^a   Fuks, François ^b  

^a Lab of Cancer Epigenetics   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

DNA methylation; Epigenetics; Hydroxymethylation; OGT; TET proteins

Indexed keywords

CYTOSINE; GENOMIC DNA; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PEPTIDES AND PROTEINS; PROTEIN TET1; PROTEIN TET2; PROTEIN TET3; RNA POLYMERASE II; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARCINOGENESIS; CATALYSIS; CELL ACTIVATION; CELL DIVISION; DEAMINATION; DEMETHYLATION; DNA ADDUCT; DNA BINDING; DNA METHYLATION; ENZYME ACTIVITY; EPIGENETIC REPRESSION; EPIGENETICS; EXCISION REPAIR; GENE LOCUS; GENE OVEREXPRESSION; GENOME IMPRINTING; HISTONE METHYLATION; HUMAN; MITOSIS; NONHUMAN; OXIDATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; RNA PROCESSING; RNA SPLICING;

DNA METHYLATION; EPIGENETICS; HYDROXYMETHYLATION; OGT; TET PROTEINS;

ANIMALS; CYTOSINE; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HUMANS; PROTO-ONCOGENE PROTEINS;

MAMMALIA;

EID: 84878425943     PISSN: 20412649     EISSN: 20412657     Source Type: Journal    
DOI: 10.1093/bfgp/elt010     Document Type: Article

References (103)

1. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010;28:1057-68.
2. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011;25:1010-22.
3. Ndlovu MN, Denis H, Fuks F. Exposing the DNA methylome iceberg. Trends Biochem Sci 2011;36:381-7.
4. Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat RevMol Cell Biol 2010;11:607-20.
5. Denis H, Ndlovu MN, Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBORep 2011;12:647-56.
6. Patra SK, Patra A, Rizzi F, et al. Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. CancerMetastasis Rev 2008;27:315-34.
7. Uribesalgo I, Di Croce L. Dynamics of epigenetic modifications in leukemia. Brief Funct Genomics 2011;10: 18-29.
8. Wyatt GR, Cohen SS. A new pyrimidine base from bacteriophage nucleic acids. Nature 1952;170:1072-3.
9. Tsukada Y. Hydroxylation mediates chromatin demethylation. J Biochem 2012;151:229-46.
10. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009;324:929-30.
11. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930-5.
12. Ono R, Taki T, Taketani T, etal. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002;62:4075-80.
13. Iyer LM, Tahiliani M, Rao A, et al. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. CellCycle 2009; 8:1698-1710.
14. Wu H, Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 2011;25:2436-52.
15. Ito S, D'Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell selfrenewal and inner cell mass specification. Nature 2010;466: 1129-33.
16. Smiley JA, Kundracik M, Landfried DA, et al. Genes of the thymidine salvage pathway: thymine-7-hydroxylase from a Rhodotorula glutinis cDNA library and iso-orotate decarboxylase from Neurospora crassa. Biochim Biophys Acta 2005; 1723:256-64.
17. Neidigh JW, Darwanto A, Williams AA, et al. Cloning and characterization of Rhodotorula glutinis thymine hydroxylase. Chem ResToxicol 2009;22:885-93.
18. Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011;333:1300-3.
19. He YF, Li BZ, Li Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011;333:1303-7.
20. Globisch D, Munzel M, Muller M, et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One 2010;5:e15367.
21. Szwagierczak A, Bultmann S, Schmidt CS, et al. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 2010;38:e181.
22. Nestor CE, Ottaviano R, Reddington J, et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res 2012;22:467-77.
23. Tollervey JR, Lunyak VV. Epigenetics: judge, jury and executioner of stem cell fate. Epigenetics 2012;7:823-40.
24. Haffner MC, Chaux A, Meeker AK, et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011;2:627-37.
25. Jin SG, Jiang Y, Qiu R, et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 2011;71: 7360-5.
26. Terragni J, Bitinaite J, Zheng Y, et al. Biochemical characterization of recombinant beta-glucosyltransferase and analysis of global 5-hydroxymethylcytosine in unique genomes. Biochemistry 2012;51:1009-19.
27. Shock LS, Thakkar PV, Peterson EJ, et al. DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. ProcNatlAcad Sci USA 2011;108:3630-5.
28. Chen H, Dzitoyeva S, Manev H. Effect of valproic acid on mitochondrial epigenetics. EurJ Pharmacol 2012;690:51-9.
29. Dzitoyeva S, Chen H, Manev H. Effect of aging on 5-hydroxymethylcytosine in brain mitochondria. Neurobiol Aging 2012;33:2881-91.
30. Hackett JA, Sengupta R, Zylicz JJ, et al. Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. Science 2012;339:448-52.
31. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447:425-32.
32. Iqbal K, Jin SG, Pfeifer GP, et al. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc Natl Acad Sci U S A 2011;108:3642-7.
33. Wossidlo M, Nakamura T, Lepikhov K, et al. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat Commun 2011; 2:241.
34. Gu TP, Guo F, Yang H, et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011;477:606-10.
35. Inoue A, Shen L, Dai Q, et al. Generation and replicationdependent dilution of 5fC and 5caC during mouse preimplantation development. Cell Res 2011;21:1670-6.
36. Inoue A, Zhang Y. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science 2011;334:194.
37. Nakamura T, Liu YJ, Nakashima H, et al. PGC7 binds histone H3K9me2 to protect against conversion of 5mC to 5hmC in early embryos. Nature 2012;486:415-9.
38. Bhattacharya SK, Ramchandani S, Cervoni N, et al. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 1999;397:579-83.
39. McKinnon PJ. DNA repair deficiency and neurological disease. Nat Rev Neurosci 2009;10:100-12.
40. Barreto G, Schafer A, Marhold J, et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007;445:671-5.
41. Le May N, Mota-Fernandes D, Velez-Cruz R, et al. NER factors are recruited to active promoters and facilitate chromatin modification for transcription in the absence of exogenous genotoxic attack. Mol Cell 2010;38:54-66.
42. Schmitz KM, Schmitt N, Hoffmann-Rohrer U, et al. TAF12 recruits Gadd45a and the nucleotide excision repair complex to the promoter of rRNA genes leading to active DNA demethylation. Mol Cell 2009;33: 344-53.
43. Cortellino S, Xu J, Sannai M, et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011;146:67-79.
44. Rai K, Huggins IJ, James SR, et al. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 2008;135:1201-12.
45. Freudenberg JM, Ghosh S, Lackford BL, et al. Acute depletion of Tet1-dependent 5-hydroxymethylcytosine levels impairs LIF/Stat3 signaling and results in loss of embryonic stem cell identity. Nucleic Acids Res 2012;40: 3364-77.
46. Wu H, D'Alessio AC, Ito S, et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011;473:389-93.
47. Dawlaty MM, Ganz K, Powell BE, et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell StemCell 2011; 9:166-75.
48. Doege CA, Inoue K, Yamashita T, etal. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 2012;488:652-5.
49. Ficz G, Branco MR, Seisenberger S, et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011;473:398-402.
50. Koh KP, Yabuuchi A, Rao S, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011;8:200-13.
51. Williams K, Christensen J, Pedersen MT, et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011;473:343-8.
52. Xu Y, Wu F, Tan L, et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 2011;42:451-64.
53. Thomson JP, Lempiainen H, Hackett JA, et al. Non-genotoxic carcinogen exposure induces defined changes in the 5-hydroxymethylome. Genome Biol 2012;13: R93.
54. Guo JU, Su Y, Zhong C, et al. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011;145:423-34.
55. Wang JH. The role of activation-induced deaminase in antibody diversification and genomic instability. Immunol Res 2013;55:287-97.
56. Storb U, Arp B. Methylation patterns of immunoglobulin genes in lymphoid cells: correlation of expression and differentiation with undermethylation. Proc Natl Acad Sci USA 1983;80:6642-6.
57. Storb U, Peters A, Kim N, et al. Molecular aspects of somatic hypermutation of immunoglobulin genes. Cold SpringHarb Symp Quant Biol 1999;64:227-34.
58. Huang Y, Pastor WA, Shen Y, et al. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 2010;5:e8888.
59. Song CX, Yi C, He C. Mapping recently identified nucleotide variants in the genome and transcriptome. NatBiotechnol 2012;30:1107-16.
60. Stroud H, Feng S, Morey Kinney S, et al. 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol 2011;12:R54.
61. Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 2011;473:394-7.
62. Yu M, Hon GC, Szulwach KE, et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 2012;149:1368-80.
63. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462:315-22.
64. Raiber EA, Beraldi D, Ficz G, et al. Genome-wide distribution of 5-formylcytosine in embryonic stem cells is associated with transcription and depends on thymine DNA glycosylase. Genome Biol 2012;13:R69.
65. Shukla S, Kavak E, Gregory M, et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 2011;479:74-9.
66. Khan DH, Jahan S, Davie JR. Pre-mRNA splicing: role of epigenetics and implications in disease. Adv BiolRegul 2012; 52:377-88.
67. Huang Y, Rao A. New functions for DNA modifications by TET-JBP. Nat StructMol Biol 2012;19:1061-4.
68. Khare T, Pai S, Koncevicius K, et al. 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. Nat Struct Mol Biol 2012;19: 1037-43.
69. Kellinger MW, Song CX, Chong J, et al. 5-Formylcytosine and 5-carboxylcytosine reduce the rate and substrate specificity of RNA polymerase II transcription. Nat Struct Mol Biol 2012;19:831-3.
70. Pan Q, Shai O, Lee LJ, et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008;40:1413-5.
71. Maciejewski JP, Padgett RA. Defects in spliceosomal machinery: a new pathway of leukaemogenesis. Br J Haematol 2012;158:165-73.
72. Song CX, Szulwach KE, Fu Y, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 2011;29:68-72.
73. Szulwach KE, Li X, Li Y, et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. NatNeurosci 2011;14:1607-16.
74. Zhou Y, Lu Y, Tian W. Epigenetic features are significantly associated with alternative splicing. BMCGenomics 2012;13: 123.
75. Deplus R, Delatte B, Schwinn MK, et al. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J 2013; Epub ahead of print.
76. Hanover JA, Krause MW, Love DC. Bittersweet memories linking metabolism to epigenetics through O-GlcNAcylation.Nat RevMol Cell Biol 2012;13:312-21.
77. Chen Q, Chen Y, Bian C, et al. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 2013; 493:561-4.
78. Fujiki R, Hashiba W, Sekine H, et al. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 2011;480:557-60.
79. Wu M, Wang PF, Lee JS, et al. Molecular regulation of H3K4 trimethylation by Wdr82, a component of human Set1/COMPASS. Mol Cell Biol 2008;28:7337-44.
80. Frauer C, Hoffmann T, Bultmann S, et al. Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain. PLoS One 2011;6:e21306.
81. Yildirim O, Li R, Hung JH, et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 2011;147: 1498-510.
82. Mellén M, Ayata P, Dewell S, et al. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 2012;151:1417-1430.
83. Choo KB. Epigenetics in disease and cancer. MalaysJ Pathol 2011;33:61-70.
84. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012;22:50-5.
85. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012;150:1135-46.
86. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012;12:599-612.
87. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23: 905-11.
88. Bejar R, Stevenson K, Abdel-Wahab O, etal. Clinical effect of point mutations in myelodysplastic syndromes. N EnglJ Med 2011;364:2496-506.
89. Patel JP, Gonen M, Figueroa ME, etal. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. NEnglJMed 2012;366:1079-89.
90. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011;118: 4509-18.
91. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011;20:11-24.
92. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25-38.
93. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-67.
94. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-43.
95. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462: 739-44.
96. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-34.
97. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alphaketoglutarate- dependent dioxygenases. Cancer Cell 2011; 19:17-30.
98. Mardis ER, Ding L, Dooling DJ, etal. Recurring mutations found by sequencing an acute myeloid leukemia genome. NEnglJMed 2009;361:1058-66.
99. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2010;28: 2348-55.
100. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24: 1302-1309.
101. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012;26: 475-80.
102. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007; 67:946-50.
103. Schiesser S, Hackner B, Pfaffeneder T, et al. Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Angew Chem Int Ed Engl 2012;51:6516-20.